Prof. PeptideProf. Peptide

Wolverine Stack

Recovery & Tissue RepairResearch-GradeCombination Blend

Last reviewed: September 20, 2026

Quick Facts

What it is
A fixed-dose combination of BPC-157 and TB-500, studied for musculoskeletal recovery and soft-tissue repair.
How it's taken
Subcutaneous injection — BPC-157 daily, TB-500 on a load-then-maintain schedule (pre-blended vials combine both in one shot)
Half-life
BPC-157 under 30 minutes in plasma; TB-500 substantially longer (dosed only 1–2× weekly)
Typical research dose
BPC-157 250–500 mcg daily + TB-500 2.0–2.5 mg twice weekly (load, weeks 1–4) then 2.0 mg once weekly (maintenance, weeks 5–8)
Research status
Not FDA-approved — research use only.
On this page
  1. 1.What is the Wolverine Stack?
  2. 2.How does the Wolverine Stack work?
  3. 3.What is the Wolverine Stack used for?
  4. 4.How long does the Wolverine Stack take to work?
  5. 5.How is the Wolverine Stack dosed?
  6. 6.How is the Wolverine Stack administered?
  7. 7.What does the Wolverine Stack stack well with?
  8. 8.What are the side effects of the Wolverine Stack?
  9. 9.Does the Wolverine Stack interact with other drugs?
  10. 10.How should the Wolverine Stack be stored?
  11. 11.What are the limitations of Wolverine Stack research?
  12. 12.Wolverine Stack FAQ
  13. 13.References
  14. 14.Published Studies

What is the Wolverine Stack?

The Wolverine Stack is a research-grade 2-component peptide blend combining BPC-157 (Body Protection Compound) and TB-500 (Thymosin Beta-4 fragment) in a single subcutaneous injection. Named for its association with rapid healing, it's the most established and widely sold of the recovery-focused peptide blends — pre-blended Wolverine has been on the research-grade market longer than any other combination product. The blend pairs BPC-157's vascular and growth-factor signaling with TB-500's actin-mediated cellular migration, targeting both the signaling that initiates tissue repair and the cellular mechanics that carry it out. Researchers stepping up to skin and inflammation coverage move to GLOW (+ GHK-Cu) and KLOW (+ GHK-Cu + KPV).

Reported benefits:

  • Accelerated tendon, ligament, and soft-tissue healing in preclinical injury models
  • Dual-pathway angiogenesis (VEGF signaling via BPC-157 + endothelial migration via TB-500)
  • Broader anti-inflammatory coverage via complementary NO-modulating and cytokine-cascade mechanisms
  • Improved cellular migration and fibroblast delivery to injury sites
  • Increased collagen synthesis paired with structural remodeling capacity
  • Reduced scar formation and fibrosis vs unassisted healing in animal models

Common research dose: BPC-157 250–500 mcg subcutaneously daily + TB-500 2.0–2.5 mg subcutaneously twice weekly (load, weeks 1–4) → 2.0 mg once weekly (maintenance, weeks 5–8). These are unverified community-reported figures — no human trial has established a dose for either compound, and the only animal study to test the two together used a very different, weight-based intraperitoneal protocol (see Dosing section). Pre-blended vials at 10 mg total (5 mg + 5 mg) or 20 mg total (10 mg + 10 mg) at fixed 1:1 ratio.

Where to buy: Sold pre-blended by some research peptide vendors and as separate vials by others. Neither component is FDA-approved. See Verified Discount Codes for current options.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 46 vendors

Also stocking Wolverine Stack

Ameano Peptides, Ascension Peptides, BioCollex, BioLongevity Labs — each carries a current price row for this compound.

Compare all 46 vendors stocking Wolverine Stack

How does the Wolverine Stack work?

The Wolverine Stack combines two peptides that hit different stages of tissue repair. BPC-157 — a pentadecapeptide originally identified in human gastric juice — rebuilds the blood supply to injured tissue, similar to how natural growth factors signal angiogenesis. TB-500, a synthetic fragment of thymosin β4 (a naturally occurring actin-binding protein), mobilizes repair cells like fibroblasts and endothelial progenitors to the injury site. Together they address the two halves of soft-tissue repair: vascular reconstruction (BPC-157) and cellular delivery (TB-500).

  1. BPC-157 — Vascular Repair and Growth Factor Signaling [1][4]. Activates the nitric oxide / VEGFR2 / FAK-paxillin axis to drive angiogenesis and endothelial protection. Upregulates VEGF and EGR-1 to promote new blood vessel formation, and stimulates collagen synthesis through downstream gene expression effects. BPC-157's plasma half-life is commonly reported as under 30 minutes, said to be offset by sustained downstream signaling and gene expression changes, though no published pharmacokinetic study or label has been identified establishing this figure for BPC-157.
  2. TB-500 — Cellular Migration and Actin Dynamics [2][5]. The synthetic active fragment of thymosin β4. Binds and sequesters monomeric G-actin to maintain a ready pool for rapid cytoskeletal remodeling — the cellular requirement for fibroblast, endothelial, and progenitor cell migration to injury sites. Also upregulates matrix metalloproteinases for ECM remodeling, mobilizes bone-marrow-derived stem cells, and supplies the anti-fibrotic Ac-SDKP fragment that biases healing toward functional tissue rather than scar.
  3. Complementary Pathways [3]. BPC-157 acts on PI3K/Akt, MAPK, and VEGF pathways; TB-500 acts on actin dynamics and integrin-mediated matrix remodeling. The two cascades are parallel but distinct — one builds the vascular substrate, the other delivers the cellular cargo. This is a mechanistic rationale for expecting broader tissue coverage from the combination, not a demonstrated outcome: the one rat Achilles tendon study that directly tested BPC-157, TB-500, and their combination against each other found that combined treatment did not outperform either agent alone, with TB-500 alone showing the strongest biomechanical result of the three treatment arms [7].
  4. Anti-Inflammatory Coverage. BPC-157 modulates nitric-oxide-mediated inflammation; TB-500 reduces inflammatory cytokine cascades and decreases apoptosis. The two anti-inflammatory mechanisms attack inflammation from different angles — useful for injury contexts where chronic NF-κB activation would otherwise impair healing.
  5. Reduced Scarring. TB-500's anti-fibrotic Ac-SDKP fragment and its ability to decrease myofibroblast numbers, paired with BPC-157's collagen-organizing growth factor profile, may reduce fibrotic scar formation compared to unassisted healing. This effect is documented in animal models but has not been quantified in controlled human trials.

What is the Wolverine Stack used for?

The Wolverine Stack is the most-studied recovery blend in research-grade peptide use. Its strongest applications are soft-tissue injuries where vascular reconstruction and cell migration are both rate-limiting — tendons, ligaments, muscle tears, and post-surgical recovery. Almost all of the applications below are extrapolated from each component's independent musculoskeletal and wound-healing literature rather than from a study of the combination — the one exception, a 2026 rat Achilles tendon study that directly tested the combination, found no additive benefit over either agent alone [7].

  1. Tendon and Ligament Repair [1][3][7]. Both peptides independently accelerate healing in Achilles, rotator-cuff, and other tendon-injury models. The combination is the most commonly studied pairing in musculoskeletal recovery research and the dominant Wolverine use case — but the one rat study to test BPC-157, TB-500, and their combination side by side found combined treatment did not outperform either component alone [7].
  2. Muscle Injury Recovery. BPC-157 accelerates functional recovery in crush-injury models; TB-500 promotes the cellular migration necessary for muscle fiber regeneration. The combination targets both signaling and structural recovery in muscle tears and overuse injuries.
  3. Wound Healing [5]. TB-500 demonstrated 42–61% improvement in wound healing rates versus controls in preclinical dermal models. BPC-157 adds growth factor support and anti-inflammatory modulation. Combined application is the rationale for post-surgical and post-procedure use.
  4. Post-Surgical Recovery. Frequently referenced in research protocols examining recovery from soft-tissue surgical procedures in animal models. The combination is also referenced in research-community discussions of recovery from joint arthroscopy and ligament reconstruction.
  5. Joint and Cartilage Support. Both peptides have been studied in cartilage damage models. BPC-157 promotes collagen synthesis; TB-500 supports cellular remodeling. Less central than the tendon/ligament use case, but established in research literature.
  6. Gastrointestinal Healing. BPC-157 has independent and substantial preclinical evidence in GI tract repair, ulcer healing, and inflammatory bowel models. TB-500 contribution to GI healing is less established. Researchers focused purely on GI work often run BPC-157 monotherapy rather than the Wolverine Stack.

How long does the Wolverine Stack take to work?

Wolverine Stack effects are sometimes reported to develop over a 6–8 week cycle, though no trial or label has been identified establishing this timeframe. BPC-157's growth factor signaling and angiogenesis acts fast — markers shift within days. TB-500's loading phase (twice weekly for 4 weeks) is designed to build tissue saturation before transitioning to once-weekly maintenance. Most research participants and users report subjective improvement in injury sites by weeks 2–3, with functional recovery accumulating through weeks 6–8.

Pre-blended Wolverine vials reach effective tissue exposure within the first week. For tendon and ligament work specifically, biomechanical strength and ultrastructural improvements typically lag the subjective “feels better” signal by 2–4 weeks. Off-cycle washout is typically 4–6 weeks before a second cycle if needed. In a rat Achilles-tendon transection model, BPC-157 produced higher load to failure and better functional scores than saline (Staresinic 2003); no study was found giving a single healing-speed percentage for these models.

How is the Wolverine Stack dosed?

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

The Wolverine Stack has never been dosed as a combination in a human study. No human clinical trial has established a dose for BPC-157, and no human clinical trial has established a dose for TB-500 either — the only study to test BPC-157, TB-500, and their combination together was a 4-week rat Achilles-tendon model (10 mcg/kg/day BPC-157, 60 mcg/kg/day TB-500, intraperitoneal), not a human or subcutaneous dose. The figures below are a research-community convention layering each peptide's own community-reported (unverified) protocol; they are not drawn from any cited trial.

Community-reported protocol (unverified):

  1. BPC-157. 250–500 mcg subcutaneously once daily, every day of the cycle. Some users split into 2× daily 8–12 hours apart.
  2. TB-500 loading phase (Weeks 1–4). 2.0–2.5 mg subcutaneously twice weekly.
  3. TB-500 maintenance phase (Weeks 5–8). 2.0 mg subcutaneously once weekly.
  4. Total cycle. 6–8 weeks active.
  5. Off period. 4–6 weeks before another cycle, if needed.
  6. Site rotation. Abdomen, thigh, upper arm. BPC-157 can be injected near the injury site (within 0.5–1 inch) for localized work. TB-500 is typically given systemically.

Pre-blended formulations (research-grade vials)

Common SKUs. Pre-blended Wolverine vials are sold as 10 mg total (5 mg BPC-157 + 5 mg TB-500) or 20 mg total (10 mg + 10 mg) at a fixed 1:1 ratio. The vial label shows the combined milligrams.

Reconstitution math. Treat the combined milligrams as the vial size in the dosing calculator. A 10 mg vial reconstituted with 2 mL bacteriostatic water yields 5 mg/mL total — and because the ratio is 1:1, every drawn unit delivers equal cargo of each peptide. Drawing 0.1 mL gives 250 mcg BPC-157 + 250 mcg TB-500 in the same shot.

Pre-blended versus separate vials. Pre-blended is more convenient and uses one injection per dose. Separate vials let researchers run non-1:1 ratios — for example, daily BPC-157 monotherapy with periodic TB-500 loading on top, which the pre-blend cannot do because the 1:1 ratio is locked. For protocols that follow the standard load-then-maintain pattern, the pre-blend is simpler.

Stepping up to GLOW or KLOW. Researchers adding skin or collagen work step up to GLOW (adds GHK-Cu). Those adding an inflammation-control layer step up to KLOW (adds KPV on top of GLOW).

Wolverine Stack is not FDA-approved. The doses above are a community convention, not derived from the cited animal literature's own weight-based dosing (10 mcg/kg/day BPC-157, 60 mcg/kg/day TB-500) or from any human trial, since none exists for either compound — there are no approved retail dosing standards for the blend.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is the Wolverine Stack administered?

The Wolverine Stack is administered by subcutaneous injection — under the skin, not into muscle — using a small insulin syringe. BPC-157 is daily; TB-500 follows its load-then-maintain schedule. Pre-blended vials combine both in a single shot; separate-vial protocols use two injections on TB-500 days.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Either consistent morning or bedtime injection works. Bedtime is a common choice to coincide with the body's natural overnight repair window.
  3. With or without food. Either is fine. Wolverine Stack components do not interact with food absorption.
  4. Site rotation. Reported practice alternates sites each injection, staying at least 1 inch from previous injection sites — mild injection-site reactions are the most commonly reported side effect.
  5. Local injection for soft-tissue work. For tendon, ligament, or post-procedure recovery, BPC-157 is often injected within 0.5–1 inch of the affected area rather than at a distant rotation site. TB-500 is given systemically regardless.
  6. Reconstitution. Use bacteriostatic water for injection (BAC water) at the volume specified by the dosing calculator. Swirl gently — do not shake — to avoid damaging the peptides.
  7. Missed dose. For BPC-157 (daily), resume on the next scheduled day. For TB-500 (load or maintenance), shift the next scheduled dose by 1–2 days if needed. The convention is not to double-dose.

What does the Wolverine Stack stack well with?

The Wolverine Stack is the 2-component baseline of the recovery-blend family. The cleanest additions are non-peptide (resistance training, protein) and stepping up to the 3-component GLOW or 4-component KLOW blend for additional skin or inflammation coverage. The thing to avoid is double-dosing BPC-157 or TB-500 by stacking with standalone protocols of either component.

  1. GLOW blend (+ GHK-Cu). Adds copper tripeptide for collagen, skin, and gene-expression effects on top of the Wolverine repair backbone. This is the blend used where skin or dermal recovery is a goal alongside tissue repair. More detail is on the GLOW page .
  2. KLOW blend (+ GHK-Cu + KPV). The most comprehensive recovery blend — adds GHK-Cu and KPV for skin remodeling and NF-κB-mediated inflammation control. This is the blend used where the target tissue is chronically inflamed or post-procedure reactive. See KLOW .
  3. GH-class peptides (CJC-1295 + Ipamorelin, MK-677). Adds growth hormone signaling for systemic anabolic and tissue-repair support. Theoretical synergy via increased IGF-1 levels. See GH Stack .
  4. IGF-1 LR3. Direct IGF-1 receptor activation paired with the local healing peptides. More aggressive systemic anabolic effect; combined cycles tend to be shorter (4–6 weeks). See IGF-1 LR3 .
  5. Resistance training + 1.2–1.6 g/kg protein. Recommended baseline for any musculoskeletal recovery protocol. Mechanical loading is required for proper tendon and muscle remodeling — peptides accelerate the substrate but do not replace the load signal.
  6. Conflicts: full-dose standalone BPC-157 or TB-500. The Wolverine Stack already contains both at meaningful doses. Stacking with standalone BPC-157 or TB-500 protocols doubles the dose without independent benefit.

What are the side effects of the Wolverine Stack?

Most reported Wolverine Stack side effects are mild and local — injection-site reactions, transient fatigue, mild gastrointestinal changes — consistent with what BPC-157 and TB-500 produce individually. There is no controlled trial of the combination, so all estimates come from each component's literature plus user reports. The most material concerns are theoretical mitogenic risk from compounded angiogenesis activity and the WADA prohibition for tested athletes.

Common (most users)

  1. Mild injection site reactions. Redness, irritation, or transient pinkness. The most commonly reported side effect.
  2. Transient fatigue. Mild post-injection tiredness, typically resolving overnight. More commonly reported on TB-500 loading-dose days.
  3. Mild GI changes. Mild loose stool or appetite changes — reflects BPC-157 activity on gut signaling.

Less common (moderate)

  1. Headache. Typically mild, more common in the first 1–2 weeks of a cycle.
  2. Lightheadedness. Usually transient and dose-related; often resolved with smaller TB-500 doses on loading days.
  3. Local soreness at injection site for soft-tissue work. Reported when BPC-157 is injected very close to a recently injured tendon or muscle. Usually transient.

Serious (rare or theoretical)

  1. Theoretical mitogenic risk. Compounded angiogenesis activity from BPC-157 + TB-500 has not been formally evaluated for tumor stimulation in humans. No signals have appeared in animal or research-community human use, but the theoretical concern is the most-discussed serious risk for the combination.
  2. Anti-doping prohibitions. BPC-157 is named on the 2026 WADA Prohibited List under S0 (Non-Approved Substances) and TB-500 under S2.3 (Growth Factors and Growth Factor Modulators). Both classes are prohibited at all times, and the Wolverine Stack contains both.
  3. Theoretical component-level concerns apply. Each component has its own individual safety considerations — see the BPC-157 and TB-500 pages.

The combined safety profile of the Wolverine Stack has not been formally studied in a controlled human trial, and no human study of the BPC-157 + TB-500 combination specifically has been identified. In the one animal study to test the combination directly, Biçer et al. 2026 reported no animal deaths, postoperative infections, wound complications, tendon reruptures, or protocol-related exclusions in any of the four treatment groups (control, BPC-157 alone, TB-500 alone, or combined) over the 4-week study [7]. A related human case series, Lee & Padgett 2021, recorded no adverse events among the 4 patients who received an intra-articular BPC-157 + thymosin beta-4 (TB4, not TB-500) combination [8] — this is a different peptide from the one sold as TB-500, so it is reported here as related context, not as safety data for this specific blend. Beyond that, most safety evidence comes from each component's independent research plus research-community use reports.

Does the Wolverine Stack interact with other drugs?

The Wolverine Stack has no well-documented systemic drug interactions. The theoretical concern most discussed in the research community is anticoagulant interaction — both BPC-157 and TB-500 are angiogenic, which could theoretically interact with warfarin or DOAC therapy, though no clinical events have been documented.

  1. Anticoagulants (warfarin, DOACs). Theoretical concern from BPC-157 and TB-500 angiogenic activity. No documented clinical events in the research literature.
  2. Other GH-class peptides. Wolverine can be stacked with CJC-1295/Ipamorelin or MK-677 — no known interaction concern beyond cumulative GI side-effect risk.
  3. Component-level interaction profiles. Cross-reference the BPC-157 and TB-500 individual peptide pages for full per-component interaction details.
  4. Alcohol. No specific interaction documented. General hydration considerations apply for any peptide injection protocol.
  5. NSAIDs. Theoretical concern that chronic NSAID use could attenuate the inflammatory signaling required for tissue repair. Often discussed in the research-community context — researchers tracking healing markers sometimes restrict NSAID use during a Wolverine cycle.

How should the Wolverine Stack be stored?

  1. Lyophilized (powder) form: -20°C long-term, 2–8°C short-term (refrigerated).
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade BPC-157 or TB-500 remains stable — this page does not state a duration as fact.
  3. Reconstitution: bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is not frozen. Freezing damages the peptides and renders them inactive.
  5. The Wolverine Stack is stored protected from light, in the original container or an amber vial.
  6. Discard if the solution is cloudy, discolored, or contains particles.

What are the limitations of Wolverine Stack research?

The Wolverine Stack is community-derived — no controlled trial has tested the two-peptide combination as a single product. All efficacy claims rest on each component's independent literature plus mechanistic reasoning about complementarity. Neither component is FDA-approved as an injectable, and the combination is uniformly prohibited in tested sport.

The Wolverine Stack is NOT FDA-approved. FDA lists BPC-157 and TB-500 among bulk drug substances “nominated but withdrawn” — previously in Category 2, now in neither Category 2 nor Category 1 (FDA page current as of April 22, 2026). The two-peptide combination has no clinical trial evidence as a single product in humans, and the mechanistic complementarity rationale should not be read as a demonstrated synergy: the one animal study to directly compare BPC-157 alone, TB-500 alone, and the combination in the same model found combined treatment did not outperform either component alone [7].

Most evidence is from animal models. BPC-157 has the most extensive preclinical literature of any research peptide, particularly in tendon and GI healing. TB-500 has strong animal-model data in dermal and cardiac healing. Controlled human trials of either compound do not exist; the only controlled trial of the combination is the 2026 rat Achilles-tendon study, which is a single exploratory study, not a replicated or human finding [7].

Compounded blends are sold as “research peptides.” Quality varies dramatically by source. A third-party HPLC certificate is the only check available — both for purity and to verify the labeled 1:1 ratio.

Anti-doping: on the 2026 WADA Prohibited List, BPC-157 is named under S0 (Non-Approved Substances) and TB-500 under S2.3 (Growth Factors and Growth Factor Modulators, as a thymosin-β4 derivative). Both classes are prohibited at all times, and the Wolverine Stack contains both compounds.

Wolverine Stack FAQ

What is the Wolverine Stack?

The Wolverine Stack is a research-grade 2-component peptide blend: BPC-157 (Body Protection Compound) + TB-500 (Thymosin Beta-4 fragment). Named for its association with rapid healing, it's the most established and widely sold of the recovery-focused peptide blends. Common SKUs are 10 mg total (5 mg + 5 mg) or 20 mg total (10 mg + 10 mg) at a fixed 1:1 ratio.

How does the Wolverine Stack compare to GLOW and KLOW?

Wolverine Stack is the 2-component baseline (BPC-157 + TB-500) for pure injury and recovery work — tendon, ligament, muscle, post-surgical tissue. GLOW adds GHK-Cu for skin and collagen remodeling on top of the same backbone. KLOW further adds KPV for inflammation control. Researchers step up: Wolverine → GLOW → KLOW as breadth of coverage expands beyond pure tissue repair.

Is the Wolverine Stack better than either peptide alone?

The one animal study that has directly tested the BPC-157 + TB-500 combination found the opposite of an additive effect: Biçer et al. 2026 (rat Achilles tendon-transection model, n=32, 8 per group — control, BPC-157 alone, TB-500 alone, and combined BPC-157 + TB-500) reported that combined treatment did not confer additional benefit over either agent alone, and TB-500 alone showed the strongest biomechanical result of the three treatment groups. A separate human case series, Lee & Padgett 2021 (a retrospective chart review, intra-articular knee injection), reported a combination arm — but the paper's own text names the second peptide as thymosin beta-4 (TB4), never TB-500, so it is not human evidence for this specific blend; in that arm, 3 of 4 patients (75%) improved versus 11 of 12 (91.6%) receiving BPC-157 alone, also showing no added benefit, for a related but distinct combination. Most research-grade users still choose the stack when dealing with significant injuries or post-surgical recovery, but neither study supports an additive claim.

How many injections per week?

During TB-500's loading phase: 9 injections per week (BPC-157 daily = 7, plus TB-500 twice weekly = 2). During TB-500's maintenance phase: 8 injections per week (BPC-157 daily, TB-500 once weekly). For pre-blended Wolverine vials, both peptides are drawn in the same injection — but most published protocols still dose them on separate schedules because TB-500's longer half-life doesn't need daily administration.

Is the Wolverine Stack FDA-approved?

No. Neither BPC-157 nor TB-500 is FDA-approved as an injectable. FDA lists BPC-157 and TB-500 among bulk drug substances “nominated but withdrawn” — previously in Category 2, now in neither Category 2 nor Category 1 (FDA page current as of April 22, 2026). Both are prohibited by the World Anti-Doping Agency (Section S0). The stack is sold as a research peptide for laboratory use only.

Can I cycle BPC-157 and TB-500 separately?

Yes — some users run BPC-157 continuously for chronic conditions and add TB-500 as a 4–6 week pulse for specific injuries. Others run a 6–8 week stack cycle and then take both off together. There is no clinically validated “best” approach. Cycling both off together is the most common protocol because it gives a clear washout period and matches typical TB-500 loading/maintenance schedules.

Where can I buy the Wolverine Stack?

Sold pre-blended by some research peptide vendors (typically 10 mg or 20 mg total) and as two separate vials by others. Pre-blended is more convenient; separate vials let researchers run non-1:1 ratios. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
  3. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. https://pubmed.ncbi.nlm.nih.gov/21030672/
  4. Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.627533/full
  5. Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:53-70. https://pubmed.ncbi.nlm.nih.gov/27450738/
  6. Rahman OF, Lee SJ, Seeds WA, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/
  7. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles Tendon Healing in Rats: A Histopathological and Biomechanical Study. Jt Dis Relat Surg. 2026;37(3):822-837. (Rat Achilles tendon-transection model, n=32; four groups — control, BPC-157 alone, TB-500 alone, and combined BPC-157 + TB-500. Combined treatment did not confer additional benefit over either agent alone.) https://pubmed.ncbi.nlm.nih.gov/42542926/
  8. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. (Retrospective case-series chart review, 16 patients; 12 received BPC-157 alone, 4 received BPC-157 + TB4 combined via intra-articular injection. Significant improvement in 11/12 (91.6%) BPC-157-alone patients versus 3/4 (75%) combination patients. The paper's own text names the second peptide "thymosin-beta-4 (TB4)," never TB-500 — a different, full-length molecule, not the fragment sold as TB-500.) https://pubmed.ncbi.nlm.nih.gov/34324435/

Published Studies

The Wolverine Stack has no human controlled trial as a combination. One 2026 rat study did directly test the combination against each component alone and against control (see below) — its finding was that combined treatment did not outperform either agent alone. The remaining studies below are the key peer-reviewed sources for each component's independent mechanism in musculoskeletal and wound-healing contexts.

Joint Diseases and Related Surgery · 2026Open Access
Effects of BPC-157 and TB-500 on Achilles Tendon Healing in Rats: A Histopathological and Biomechanical Study →

Biçer O, Adanir O, Güleryüz Y, et al.

The only study to date that directly tests the Wolverine Stack combination rather than each component separately. Thirty-two rats underwent Achilles tendon transection and repair, then were randomized to control, BPC-157 alone (10 mcg/kg/day IP), TB-500 alone (60 mcg/kg/day IP), or the combination, for four weeks. TB-500 alone produced the strongest biomechanical result (significantly higher maximum load to failure, p<0.05) and significantly better histopathology scores; BPC-157 alone showed numerically better histopathology without reaching statistical significance. The combined BPC-157 + TB-500 group did not outperform either agent alone — the paper's own conclusion is that combination therapy did not confer additional benefit, possibly because the two peptides converge on shared downstream pathways. This is a single exploratory animal study, not a replicated or human finding, but it is the closest thing to direct evidence on whether the Wolverine Stack combination beats its components.

HSS Journal · 2025Open Access
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review →

Vasireddi N, Hahamyan H, Salata MJ, et al.

The most current systematic review of BPC-157 for musculoskeletal injuries — directly relevant to the Wolverine Stack's primary use case. Across 36 studies, BPC-157 consistently promoted healing of muscle, tendon, ligament, and bone injuries by upregulating growth factors and reducing inflammation. The mechanism involves FAK-paxillin signaling, VEGFR2-Akt-eNOS activation, and nitric oxide modulation — pathways distinct from TB-500's actin-based mechanism, providing the rationale for combining the two.

Expert Opinion on Biological Therapy · 2012Paywalled
Thymosin β4: A Multi-Functional Regenerative Peptide →

Goldstein AL, Hannappel E, Sosne G, Kleinman HK

The foundational review for TB-500's contribution to the Wolverine Stack. The paper documents thymosin β4's role in actin-mediated cell migration, stem cell mobilization, and angiogenesis — mechanisms upstream and complementary to BPC-157's downstream signaling effects on tissue repair. Together the two peptides target both the cellular migration phase of healing (TB-500) and the tissue remodeling and vascularization phase (BPC-157) — the mechanistic argument for using them in combination.

JAAOS Global Research & Reviews · 2026Open Access
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions →

Rahman OF, Lee SJ, Seeds WA, et al.

A 2025 orthopaedic review that specifically discusses BPC-157 and TB-500 together as wound-healing peptides acting on complementary molecular signaling networks. The paper notes BPC-157 acts on PI3K/Akt, MAPK, and VEGF pathways while TB-500 targets actin dynamics and integrin-mediated matrix remodeling — two parallel but distinct repair cascades. This is the closest published scientific justification for the Wolverine Stack as a combination, explicitly describing the two compounds' complementary mechanisms in the same research context.

Frontiers in Pharmacology · 2021Open Access
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing →

Sikiric P, Hahm KB, Blagaic AB, et al.

Comprehensive review of BPC-157's wound healing evidence that helps contextualize how it fits alongside TB-500 in a combination protocol. The paper covers BPC-157's role in accelerating wound closure, promoting collagen deposition, and maintaining vascular integrity — downstream tissue remodeling effects that complement TB-500's upstream role in recruiting progenitor cells and promoting cell migration. Cellular recruitment followed by structural repair is the biological rationale for the Wolverine Stack.

Vitamins and Hormones · 2016Paywalled
Thymosin β4 Promotes Dermal Healing →

Kleinman HK, Sosne G

Focused review of TB-500's dermal-healing data. Across multiple animal wound-healing models, TB-500 demonstrated 42–61% improvement in healing rate versus controls. The paper documents the actin-sequestration mechanism (releasing G-actin from intracellular pools to enable rapid cytoskeletal remodeling at the wound front) and the anti-fibrotic Ac-SDKP fragment effect. This dermal-healing data is the empirical foundation for TB-500's contribution to the Wolverine Stack's wound and post-surgical applications.

RecoveryTissue RepairAnti-InflammatoryCombination BlendPreclinical

Related Peptides

BPC-157TB-500GHK-CuKPV

Related Blends

GLOWKLOW

We may earn commissions from peptide vendor affiliate links.

Have a question about Wolverine Stack? Send us an email